A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Clinical case use bevacizumab for patient with metastatic ovarian cancer
2014
Opuholi Ženskoj Reproduktivnoj Sistemy
Preserved Fulltext
High incidence and mortality rate for ovarian cancer patients, short-term survival until relapse, repeated following surgeries and chemo- therapy, and also low survival rates make the problem of treatment of this pathology vital. Nowadays combination of platinum and paclitaxel (gemcitabine) in addition with targeted therapy (bevacizumab) is the most effective chemotherapy for first and second line of stages III and IV ovarians cancer. Considering high efficacy of these combinations aimed at the
doi:10.17650/1994-4098-2014-0-2-68-72
doaj:6d3dd22f6e0d4c05996d5372c144eff3
fatcat:3dkybmcvezbpxdv2yvkojzke3a